MetaCap

AnaptysBio Earnings

NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD

46.63-0.77 (-1.62%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AnaptysBio earnings summary

In its most recent report on Nov 12, 2026 (Sep/2026), ANAB posted EPS of $0.11 versus the $0.41 consensus estimate, a negative surprise of 73.2%. AnaptysBio beat the consensus EPS estimate in 2 of the last 3 quarters, with a median surprise of +26.8%. Quarterly EPS is down 93.4% from the same quarter a year earlier.

Across the last 16 reports, ANAB shares moved an average of 6.3% (in either direction) in the first trading session after results, rising 7 times and falling 9 times.

Summary generated from market data by MetaCap's automated system. Methodology

ANAB earnings history

AnaptysBio reported EPS versus estimates
Report dateEPS est.EPS actualSurprisePrice reaction
Nov 12, 2026$0.41$0.11-73.2%+0.8%
Nov 10, 2026$0.41$0.52+26.8%+0.8%
Nov 3, 2026$0.41$0.52+26.8%-0.4%
May 12, 2026—$-1.84—-5.4%
Mar 3, 2026—$1.66—+17.0%
Nov 4, 2025—$0.52—-14.7%
Aug 6, 2025—$-1.34—-4.2%
May 5, 2025—$-1.28—+3.2%
Feb 27, 2025—$-0.43—-2.9%
Nov 5, 2024—$-1.14—-10.8%
Aug 5, 2024—$-1.71—+2.9%
May 9, 2024—$-1.64—+7.1%
Mar 11, 2024—$-1.59—-7.6%
Nov 2, 2023—$-1.41—-18.4%
Aug 7, 2023—$-1.50—+3.2%
May 11, 2023—$-1.58—-1.6%

Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.

Related